{"filing":{"accession_number":"0001104659-26-088380","cik":"0001971387","ticker":"LIMNW","company_name":"Liminatus Pharma, Inc.","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"tm2621658d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926088380/tm2621658d1_8k.htm"},"events":[{"id":21904,"run_id":19770,"accession_number":"0001104659-26-088380","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The disclosure explicitly addresses Nasdaq compliance with the stockholders' equity requirement and warns that \"if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to future delisting.\" This is a clear notice of delisting risk tied to failure to satisfy a continued listing rule, which is the defining characteristic of the delisting_risk event type.","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21674,"accession_number":"0001104659-26-088380","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The disclosure explicitly addresses Nasdaq compliance with the stockholders' equity requirement and warns that \"if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to future delisting.\" This is a clear notice of delisting risk tied to failure to satisfy a continued listing rule, which is the defining characteristic of the delisting_risk event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:07:59.140509+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21674,"accession_number":"0001104659-26-088380","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The disclosure explicitly addresses Nasdaq compliance with the stockholders' equity requirement and warns that \"if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to future delisting.\" This is a clear notice of delisting risk tied to failure to satisfy a continued listing rule, which is the defining characteristic of the delisting_risk event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T10:07:59.140509+00:00","company_name":"Liminatus Pharma, Inc.","ticker":"LIMNW","filing_date":"2026-07-29"}]}